COMPANY

Lakewood-Amedex

Keywords: infectious disease diabetic foot ulcers Diabetic Foot Infection Chronic Diabetic Foot Ulcers Antimicrobial agent Bisphosphocin Nu-3

Location: University Park, FL · source · Oct 14, 2026

Profile checked Oct 10, 2026

Timeline

Aug 14, 2026 Trial start 2: Phase 2a Dose Finding Study of Nu-3 Gel in Subjects With Mild iDFU source ↗
2025-12 Trial start Phase 2: Nu-3 Gel for Infected Diabetic Foot Ulcers source ↗
Mar 11, 2022 Trial start Phase 2: Nu-3 Topical Gel for Treatment of Diabetic Foot Ulcer source ↗
2016-04 Trial start Phase 1/Phase 2: Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus source ↗

2027-01 (ESTIMATED) · 2 · Phase 2a Dose Finding Study of Nu-3 Gel in Subjects With Mild iDFU · NCT07565506

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT07565506	Phase 2a Dose Finding Study of Nu-3 Gel in Subjects With Mild iDFU	2	Recruiting	Aug 14, 2026	2027-01 (estimated)
NCT06020235	Nu-3 Gel for Infected Diabetic Foot Ulcers	Phase 2	Not yet recruiting	2025-12	2026-06 (estimated)
NCT05276401	Nu-3 Topical Gel for Treatment of Diabetic Foot Ulcer	Phase 2	Terminated	Mar 11, 2022	May 18, 2022 (actual)
NCT02737722	Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus	Phase 1/Phase 2	Completed	2016-04	2017-08 (actual)